Written by :
Posted on :

May 1, 2021

Kolosis BIO Appoints Maxwell Hunter as its Chief Operations Officer

Salt Lake City, Utah, May 1, 2021

Kolosis BIO, a privately-held pure-play orthobiologics company, announced today the appointment of Maxwell Hunter as the company’s Chief Operating Officer.

“Our executive team is bolstered tremendously by the addition of Max as our new COO,” said Keegan Begley, President at Kolosis. “We keenly understand that responsiveness to our sales channel is key to our success and that it all begins with our operations support. Max brings valuable experience in building systems to support complex commercial operations and we look forward to his leadership in helping us build a scalable foundation for our planned growth.”

Prior to joining Kolosis, Maxwell served as Chief Financial Officer at Titan Mobile where he xxxxxxx. Prior to that, Maxwell was CFO at multiple large land development and residential home building companies in Salt Lake City.

“I’m thrilled to join Kolosis so early in its pathway to commercial success,” said Maxwell Hunter. “I look forward to making the company an industry leader in providing resources and support to sales partners, caregivers, and our strategic partners.”

About Kolosis BIO:

Kolosis BIO is a leading provider of innovative biologic solutions, dedicated to commercializing cutting-edge technologies and delivering market-leading products to the orthopedic industry. As a pure-play biologics company, Kolosis BIO exclusively partners with MTF Biologics to offer superior quality bone graft technologies such as Kore Fiber, a 100% cortical fiber allograft and Prime HD, a pre-hydrated DBM. These allografts are backed by MTF’s proprietary aseptic processing methods that optimally preserve matrix structures and osteoinductive properties.

As the company looks to the future, Kolosis is dedicated to driving innovation in the biologics field, expanding its product offerings and pushing the boundaries of science to enhance patient outcomes. With a focus on relentless execution and bold technologies, Kolosis BIO endeavors to become a leading force in the biologics market. For more information, please visit

About MTF Biologics:

MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. They provide unmatched service, resources, and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers, and clinicians and scientists.

The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized communications and technology expertise to organ, tissue, and eye procurement organizations, as well as the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation), expands its reach to patients across the globe. For more information, visit